Clinical Trials Experience: The following adverse drug reactions (ADRs) in Table 11 were identified with incidence rates greater than 0.01% in celecoxib group and greater than those reported in placebo group, during 12 placebo- and/or active-controlled clinical trials of treatment duration up to 12 weeks at daily doses from 100 mg up to 800 mg in adults.
The frequencies on the ADRs in Table 11 are updated based on a more recent pooling of 89 randomized, controlled clinical trials data representing clinical exposure in 38,102 patients taking celecoxib. (See Table 11.)
Click on icon to see table/diagram/image
The following additional adverse drug reactions* in Table 12 were identified with incidence rates greater than placebo in long-term polyp prevention studies of duration up to 3 years at daily doses from 400 mg up to 800 mg (see Pharmacology: Pharmacodynamics under Actions). (See Table 12.)
Click on icon to see table/diagram/image
Post-marketing Experience: Adverse reactions identified from post-marketing experience are provided as follows. Even though these were identified as reactions from post-marketing reports, trial data was consulted to estimate frequency. As previously, frequencies are based on a pooling of trials representing exposure in 38,102 patients. (See Table 13.)
Click on icon to see table/diagram/image
View ADR Monitoring Form